|
Dec 22
|
First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
|
|
Nov 30
|
Registrational Phase III CLARIFY trial in prostate cancer commences
|
|
Nov 30
|
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
|
|
Nov 29
|
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
|
|
Oct 26
|
Clarity and PSI kick off SAR-bisPSMA Phase III
|